Page 56 - Medication Guide News Today

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from...

First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significa...

KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvant Immunotherapy in RCC First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting Merck known as MSD outside the United States and Canada, today announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the potential adjuvant … KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvan...

First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyKENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck (NYSE: MRK),...

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc.,

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous04.06.2021 / 19:32 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refract...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety...

/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...

Phase 3 Maintenance Results Show Patients with Crohns Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year - In Crohns disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1] - The overall safet...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma